IP Library Assignment 029198/0319
Patent Assignment
Reel/Frame 029198/0319

Change of Name

Recorded: 2012-10-25 Pages: 5
Assignor
AMYLIN PHARMACEUTICALS, INC.
Executed: 2012-08-08
Assignee
AMYLIN PHARMACEUTICALS, LLC
9360 TOWNE CENTRE DRIVE, ATTN: INTELLECTUAL PROPERTY GROUP, SAN DIEGO, CALIFORNIA, 92121
Covered Properties (19)
Use of Exendins and Agonists Thereof for the Reduction of Food Intake
Patent: 6,956,026 →
Application: 09/003,869 →
Publication: US 2002/0137666
Formulations for Amylin Agonist Peptides
Patent: 6,410,511 →
Application: 09/005,262 →
Publication: US 2001/0043934
Polynucleotides Encoding Proexendin, and Methods and Uses Thereof
Patent: 6,723,530 →
Application: 09/019,172 →
Novel Anti-Diabetic Peptides
Patent: 6,087,334 →
Application: 09/138,056 →
Metabolic Intervention with Glp-1 to Improve the Function of Ischemic and Reperfused Tissue
Patent: 6,284,725 →
Application: 09/302,596 →
Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
Patent: 6,506,724 →
Application: 09/323,867 →
Lipid Matrix-Assisted Chemical Ligation and Synthesis of Membrane Polypeptides
Patent: 6,451,543 →
Application: 09/384,302 →
Novel Exendin Agonist Compounds
Patent: 7,220,721 →
Application: 09/554,531 →
Novel Exendin Agonist Compounds
Patent: 7,223,725 →
Application: 09/554,533 →
Modified Exendins and Exendin Agonists
Patent: 6,924,264 →
Application: 09/561,226 →
Methods for Regulating Gastrointestinal Motility
Patent: 6,608,029 →
Application: 09/576,062 →
Novel Mixed Amylin Activity Compounds
Patent: 6,936,584 →
Application: 09/622,104 →
Inotropic and Diuretic Effects of Exendin and Glp-1
Patent: 6,703,359 →
Application: 09/622,105 →
Human Appetite Control by Glucagon-Like Peptide Receptor Binding Compounds
Patent: 6,998,387 →
Application: 09/646,433 →
Exendin Improves Beta-Cell Response in Subjects with Impaired Glucose Tolerance
Patent: 7,265,087 →
Application: 09/719,410 →
Uncoupling Protein 4 (Ucp-4)
Patent: 6,602,694 →
Application: 09/743,847 →
Treatment of Acute Coronary Syndrome with Glp-1
Patent: 6,706,689 →
Application: 09/859,804 →
Publication: US 2002/0107206
Novel Exendin Agonist Formulations and Methods of Administration Thereof
Patent: 6,902,744 →
Application: 09/889,330 →
Methods for Glucagon Suppression
Patent: 6,872,700 →
Application: 09/889,331 →
Related Assignments (3)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0342 →
Release of Security Interest Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0626 →
Amylin Pharmaceuticals, Llc Assigns an Equal and Undivided One-Half of Its Entire Right, Title and Interest to Astrazeneca Pharmaceuticals Lp Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →